<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Braz J Cardiovasc Surg</journal-id><journal-id journal-id-type="iso-abbrev">Braz J Cardiovasc Surg</journal-id><journal-id journal-id-type="publisher-id">rbccv</journal-id><journal-title-group><journal-title>Brazilian Journal of Cardiovascular Surgery</journal-title></journal-title-group><issn pub-type="ppub">0102-7638</issn><issn pub-type="epub">1678-9741</issn><publisher><publisher-name>Sociedade Brasileira de Cirurgia Cardiovascular</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">27556306</article-id><article-id pub-id-type="pmc">5062732</article-id><article-id pub-id-type="doi">10.5935/1678-9741.20160025</article-id><article-categories><subj-group subj-group-type="heading"><subject>Original Articles</subject></subj-group></article-categories><title-group><article-title>Associated Clinical and Laboratory Markers of Donor on Allograft
Function After Heart Transplant</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Braulio</surname><given-names>Renato</given-names></name><degrees>MD, MSc, PhD</degrees><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="corresp" rid="c1"/></contrib><contrib contrib-type="author"><name><surname>Sanches</surname><given-names>Marcelo Dias</given-names></name><degrees>MD, PhD</degrees><xref ref-type="aff" rid="aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Teixeira Junior</surname><given-names>Antonio L&#x000fa;cio</given-names></name><degrees>MD, MSc, PhD</degrees><xref ref-type="aff" rid="aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Costa</surname><given-names>Paulo Henrique Nogueira</given-names></name><degrees>MD, MSc</degrees><xref ref-type="aff" rid="aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Moreira</surname><given-names>Maria da Consola&#x000e7;&#x000e3;o Vieira</given-names></name><degrees>MD, MSc, PhD</degrees><xref ref-type="aff" rid="aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Rocha</surname><given-names>Monaliza Angela</given-names></name><xref ref-type="aff" rid="aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>de Andrade</surname><given-names>Silvio Amadeu</given-names></name><degrees>MD</degrees><xref ref-type="aff" rid="aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Gelape</surname><given-names>Cl&#x000e1;udio L&#x000e9;o</given-names></name><degrees>MD, MSc, PhD</degrees><xref ref-type="aff" rid="aff1">1</xref></contrib><aff id="aff1"><label>1</label>Federal University of Minas Gerais (UFMG), Belo
Horizonte, MG, Brazil.</aff></contrib-group><author-notes><corresp id="c1">Correspondence Address: Renato Braulio, Federal University of Minas
Gerais, Av. Prof. Alfredo Balena, 110 - Santa Efig&#x000ea;nia - Belo Horizonte,
MG, Brazil - Zip code: 30130-100. E-mail:
<email>renatobraulio1000@gmail.com</email></corresp></author-notes><pub-date pub-type="epub-ppub"><season>Mar-Apr</season><year>2016</year></pub-date><!--Fake ppub date generated by PMC from publisher
							pub-date/@pub-type='epub-ppub' --><pub-date pub-type="ppub"><season>Mar-Apr</season><year>2016</year></pub-date><volume>31</volume><issue>2</issue><fpage>89</fpage><lpage>97</lpage><history><date date-type="received"><day>04</day><month>10</month><year>2015</year></date><date date-type="accepted"><day>08</day><month>3</month><year>2016</year></date></history><permissions><license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by/4.0/"><license-p>This is an Open Access article distributed under the terms of the
Creative Commons Attribution License, which permits unrestricted use,
distribution, and reproduction in any medium, provided the original work is
properly cited.</license-p></license></permissions><abstract><sec><title>Introduction</title><p>Primary graft dysfunction is a major cause of mortality after heart
transplantation.</p></sec><sec><title>Objective</title><p>To evaluate correlations between donor-related clinical/biochemical markers
and the occurrence of primary graft dysfunction/clinical outcomes of
recipients within 30 days of transplant.</p></sec><sec><title>Methods</title><p>The prospective study involved 43 donor/recipient pairs. Data collected from
donors included demographic and echocardiographic information, noradrenaline
administration rates and concentrations of soluble tumor necrosis factor
receptors (sTNFR1 and sTNFR2), interleukins (IL-6 and IL-10), monocyte
chemoattractant protein-1, C-reactive protein and cardiac troponin I. Data
collected from recipients included operating, cardiopulmonary bypass,
intensive care unit and hospitalization times, inotrope administration and
left/right ventricular function through echocardiography.</p></sec><sec><title>Results</title><p>Recipients who developed moderate/severe left ventricular dysfunction had
received organs from significantly older donors (<italic>P</italic> =0.020).
Recipients from donors who required moderate/high doses of noradrenaline
(&#x0003e;0.23 &#x000b5;g/kg/min) around harvesting time exhibited lower
post-transplant ventricular ejection fractions (<italic>P</italic> =0.002)
and required longer CPB times (<italic>P</italic> =0.039). Significantly
higher concentrations of sTNFR1 (<italic>P</italic> =0.014) and sTNFR2
(<italic>P</italic> =0.030) in donors were associated with reduced
intensive care unit times (&#x02264;5 days) in recipients, while higher donor
IL-6 (<italic>P</italic> =0.029) and IL-10 (<italic>P</italic> =0.037)
levels were correlated with reduced hospitalization times (&#x02264;25 days)
in recipients. Recipients who required moderate/high levels of noradrenaline
for weaning off cardiopulmonary bypass were associated with lower donor
concentrations of sTNFR2 (<italic>P</italic> =0.028) and IL-6
(<italic>P</italic> =0.001).</p></sec><sec><title>Conclusion</title><p>High levels of sTNFR1, sTNFR2, IL-6 and IL-10 in donors were associated with
enhanced evolution in recipients. Allografts from older donors, or from
those treated with noradrenaline doses &#x0003e;0.23 &#x000b5;g/kg/min, were more
frequently affected by primary graft dysfunction within 30 days of
surgery.</p></sec></abstract><kwd-group><kwd>Heart Transplantation</kwd><kwd>Tissue Donors</kwd><kwd>Biomarkers</kwd><kwd>Norepinephrine</kwd><kwd>Primary Graft Dysfunction</kwd></kwd-group></article-meta></front><body><table-wrap id="t8" orientation="portrait" position="anchor"><table frame="hsides" rules="groups" style="background-color:#e6e7e8"><colgroup span="1"><col width="6%" span="1"/><col width="41%" span="1"/><col width="6%" span="1"/><col width="6%" span="1"/><col width="41%" span="1"/></colgroup><thead><tr><th align="left" colspan="2" rowspan="1">Abbreviations, acronyms &#x00026; symbols</th><th align="left" style="background-color:#ffffff" rowspan="1" colspan="1">&#x000a0;</th><th rowspan="1" colspan="1">&#x000a0;</th><th rowspan="1" colspan="1">&#x000a0;</th></tr></thead><tbody><tr><td rowspan="1" colspan="1">BNP</td><td rowspan="1" colspan="1">= B-type natriuretic peptide</td><td style="background-color:#ffffff" rowspan="1" colspan="1">&#x000a0;</td><td rowspan="1" colspan="1">PGD</td><td rowspan="1" colspan="1">= Primary graft dysfunction</td></tr><tr><td rowspan="1" colspan="1">CPB</td><td rowspan="1" colspan="1">= Cardiopulmonary bypass</td><td style="background-color:#ffffff" rowspan="1" colspan="1">&#x000a0;</td><td rowspan="1" colspan="1">PVR</td><td rowspan="1" colspan="1">= Pulmonary vascular resistance</td></tr><tr><td rowspan="1" colspan="1">CRP</td><td rowspan="1" colspan="1">= Cardiopulmonary bypass</td><td style="background-color:#ffffff" rowspan="1" colspan="1">&#x000a0;</td><td rowspan="1" colspan="1">sTNFR1</td><td rowspan="1" colspan="1">= Soluble tumor necrosis factor receptors 1</td></tr><tr><td rowspan="1" colspan="1">CRP</td><td rowspan="1" colspan="1">= Cardiopulmonary bypass</td><td style="background-color:#ffffff" rowspan="1" colspan="1">&#x000a0;</td><td rowspan="1" colspan="1">sTNFR2</td><td rowspan="1" colspan="1">= Soluble tumor necrosis factor receptors 2</td></tr><tr><td rowspan="1" colspan="1">FiO<sub>2</sub></td><td rowspan="1" colspan="1">= Fraction of inspired oxygen</td><td style="background-color:#ffffff" rowspan="1" colspan="1">&#x000a0;</td><td rowspan="1" colspan="1">TBI</td><td rowspan="1" colspan="1">= Traumatic brain injury</td></tr><tr><td rowspan="1" colspan="1">IL</td><td rowspan="1" colspan="1">= Interleukins</td><td style="background-color:#ffffff" rowspan="1" colspan="1">&#x000a0;</td><td rowspan="1" colspan="1">TNIU</td><td rowspan="1" colspan="1">= Troponin I ultra</td></tr><tr><td rowspan="1" colspan="1">IL</td><td rowspan="1" colspan="1">= Intensive care unit</td><td style="background-color:#ffffff" rowspan="1" colspan="1">&#x000a0;</td><td rowspan="1" colspan="1">VEF</td><td rowspan="1" colspan="1">= Ventricular ejection fraction</td></tr><tr><td rowspan="1" colspan="1">IL</td><td rowspan="1" colspan="1">= Monocyte chemoattractant protein-1</td><td style="background-color:#ffffff" rowspan="1" colspan="1">&#x000a0;</td><td rowspan="1" colspan="1">&#x000a0;</td><td rowspan="1" colspan="1">&#x000a0;</td></tr></tbody></table></table-wrap><sec sec-type="intro"><title>INTRODUCTION</title><p>Heart failure is one of the major causes of hospitalization worldwide, particularly
for individuals aged 65 years and above. In cases where the condition becomes
clinically refractory, heart transplantation appears to be the best therapy with
satisfactory outcomes having been established during the last
decades<sup>[<xref rid="r1" ref-type="bibr">1</xref>]</sup>.
However, the number of heart transplants performed annually has leveled off over the
last 20 years mainly because of the chronic shortage of viable donated organs. This
situation has led transplant centers to accept hearts from marginal donors in an
effort to expand the pool of organs available to severely ill patients on the
priority waiting list, and the strategy has yielded satisfactory
results<sup>[<xref rid="r2" ref-type="bibr">2</xref>]</sup>.</p><p>The principal criteria for rejecting heart donors, apart from age and other
harvesting-related issues, are systolic dysfunction and myocardial hypertrophy on
echocardiography since they represent key risk factors for post-transplant
outcome<sup>[<xref rid="r3" ref-type="bibr">3</xref>]</sup>.
However, appropriate clinical management of the potential organ donor can often
alleviate such problems, thereby increasing the number of eligible donors and
optimizing organ function for the purposes of transplantation<sup>[<xref rid="r4" ref-type="bibr">4</xref>]</sup>. Nevertheless, despite
careful assessment and treatment of potential donors, primary graft dysfunction
(PGD) still occurs in approximately 20% of cases and is one of the major causes of
mortality after heart transplantation even when quality donors are
involved<sup>[<xref rid="r5" ref-type="bibr">5</xref>]</sup>.</p><p>Donor-specific clinical or biochemical markers that can be used to predict the
quality of a cardiac graft have yet to be firmly established. However, some evidence
suggests that increased levels of procalcitonin, cardiac troponin T (cTnT) and
B-type natriuretic peptide (BNP) may be independent predictors of
PGD<sup>[<xref rid="r6" ref-type="bibr">6</xref>,<xref rid="r7" ref-type="bibr">7</xref>]</sup>. In addition, the
inflammatory status of the potential donor, as evaluated from cytokine levels,
appears to influence the quality of the allograft, while doses of inotropic agents
(catecholamines such as noradrenaline, adrenaline, dopamine or dobutamine)
administered at the time of harvesting represent an important risk factor for
PGD<sup>[<xref rid="r8" ref-type="bibr">8</xref>-<xref rid="r12" ref-type="bibr">12</xref>]</sup>.</p><p>Most of the practices and guidelines relating to the management of donor organs
follow predefined physiological and biochemical parameters in order to improve graft
function and patient survival, while more novel approaches include non-conventional
variables such as the measurement of plasma cytokines to determine the inflammatory
status of the donor<sup>[<xref rid="r11" ref-type="bibr">11</xref>]</sup>. However, the quality of the allograft may depend on
the interaction between pro- and antiinflammatory cytokines and on the clinical
characteristics of the donor, including age, doses of inotropic agents administered,
comorbidities, functional and structural alterations of the cardiac muscle as
assessed by echocardiography.</p><p>In consideration of the above, the aims of the present study were to evaluate
potential donor-related clinical (age, doses of noradrenaline received),
echocardiographic (left ventricular ejection fraction and right ventricular
function) and laboratory markers of allograft function and/or postoperative PGD, and
to determine the association between these markers and the early outcomes of
recipients.</p></sec><sec sec-type="methods"><title>METHODS</title><p>The study was approved by the local Research Ethics Committee (protocol no. ETIC
0517.0.203.000-10), and was performed according to the principles of the Declaration
of Helsinki. The aims and objectives of the investigation were explained carefully
to all potential participants, or their legally authorized representative where
appropriate, who were then invited to sign the document of written informed consent
to take part in the study.</p><sec><title>Patients</title><p>The prospective study involved a paired population comprising 43 donors and 43
recipients who underwent heart transplantation at the University Hospital,
Federal University of Minas Gerais, between January 2012 and November 2013. All
donors and recipients included in the study were aged 18 years or more and were
pairwise compatible for the transplant procedure. Pairs were excluded from the
study either when informed consent could not be obtained from both potential
participants or when the donated organ could not be harvested for whatever
motive.</p></sec><sec><title>Assessment of Donors and Recipients</title><p>Potential heart donors were evaluated with regard to demographic data and
clinical and biochemical parameters collected. In addition, various other
measurements were performed, including systolic and diastolic arterial pressures
(along with the mean of the two values), ventilation parameters [fraction
of inspired oxygen (FiO<sub>2</sub>) and oxygen saturation levels],
echocardiographic data [left ventricular ejection fraction (VEF) and
anatomical, structural and functional information], times of
hospitalization and diagnosis of brain death, and doses of noradrenaline
administered. Information regarding the usage and doses of noradrenaline was
obtained at the time of admission to hospital. In addition, these data, along
with those relating to pressure and ventilation, were collected 48 h and 24 h
prior to harvesting, at the preoperative stage immediately before transportation
to the operating theatre, at the initiation of harvesting and prior to aortic
clamping.</p><p>A sample (10 mL) of arterial blood for biochemical analysis was taken from each
donor around the time of organ harvesting, transferred to a sterile vial
containing heparin (Becton &#x00026; Dickinson, Franklin Lakes, NJ, USA) and
centrifuged at 3000 rpm for 10 min. Five 1 mL aliquots of plasma were separated
from each sample, labeled with the names of the donor and the recipient,
transported in ice and stored in the freezer at -70&#x000b0;C until required for
analysis. Frozen samples were subsequently thawed at room temperature and the
concentrations of soluble tumor necrosis factor receptors 1 and 2 (sTNFR1 and
sTNFR2, respectively), interleukin-6 (IL-6), IL-10 and monocyte chemoattractant
protein-1 (MCP1) were measured using sandwich enzyme-linked immunosorbent assay
(ELISA) kits (R&#x00026;D Systems, Minneapolis, MN, USA), while those of C-reactive
protein (CRP) and cTnI were determined using VIDAS<sup>&#x000ae;</sup>QCV and
Troponin I ultra (TNIU) assay kits (bioM&#x000e9;rieux, S&#x000e3;o Paulo, SP,
Brazil), respectively.</p><p>Recipients were evaluated with regard to demographic data and clinical and
biochemical parameters collected. Parameters relating to the surgical procedure
[cardiopulmonary bypass (CPB), aortic clamping, ischemia and operating
times), left VEF, right ventricular function, usage of inotrope/vasodilator
medication during and after transplantation, occurrence of PGD, and
hospitalization and intensive care unit (ICU) times were recorded. Data relating
to the usage of inotropes/vasodilators were obtained immediately before
induction of anesthesia, 10 min after withdrawal of CPB, immediately before to
transfer to ICU, after one, six, 24 and 48 h in ICU and seven days after
surgery.</p></sec><sec><title>Data Analysis and Definitions</title><p>Clinical and biochemical data pertaining to donors were associated with recipient
outcomes assessed as mortality, left/right ventricular dysfunction on
echocardiography, requirement of high doses of inotropes and/or circulatory
support with intra-aortic balloon pump for maintenance of cardiac output,
together with CPB, hospitalization, operating and ICU times. Graft dysfunction
was defined as the need for circulatory support (intra-aortic balloon) and/or
intravenous administration of high levels of catecholamines (noradrenaline) for
withdrawal of CPB, and the presence of moderate or severe postoperative
ventricular systolic dysfunction (left or right) on echocardiography.</p><p>Noradrenaline doses were defined as low (&#x02264; 0.23 &#x000b5;g/kg/min),
moderate (0.24 to 0.46 &#x000b5;g/kg/min) or high (&#x0003e; 0.46 &#x000b5;g/kg/min).
The heart transplant team rejected all allografts from donors who had received
noradrenaline doses considered excessively high (&#x0003e; 0.69 &#x000b5;g/kg/min)
during their permanence in the allocation centers, except in cases where time
and clinical conditions allowed restoration of cardiac function. Left
ventricular dysfunctions were defined as absent (VEF &#x02265; 60%), mild (VEF
&#x0003c; 60 to &#x0003e; 45%), moderate (VEF &#x02264; 45 to &#x0003e; 30%) or severe (VEF
&#x02264; 30%). Right ventricular dysfunctions (absent, mild, moderate or severe)
were defined by subjective analysis of the echocardiographic data. ICU and
hospitalization times of &#x02264; 5 and &#x02264; 25 days, respectively, were
considered favorable clinical evolutions (suitable outcomes).</p></sec><sec><title>Surgical Procedures</title><p>All transplants were performed by the same surgical team using the bicaval
anastomosis technique and following identical procedures for the induction and
maintenance of anesthesia (as appropriate) and surgery<sup>[<xref rid="r4" ref-type="bibr">4</xref>,<xref rid="r13" ref-type="bibr">13</xref>]</sup>. Cardioplegia in the donor was performed using
20 mL/kg of Celsior cardioplegic infusion (Genzyme Polyclonals, Champagne au
Mont D'Or, France) at 4&#x000b0;C. The excised heart was soaked in 200 mL of
cardioplegic solution at 4&#x000b0;C and transferred to a plastic bag, the temperature
of which was maintained during transportation by ice contained in two outer
plastic bags. During the implant, the heart received intermittent cardioplegia
every 30 min with 10 mL/kg of Celsior cardioplegic infusion.</p></sec><sec><title>Statistical Analysis</title><p>Descriptive statistics were expressed in terms of mean, standard deviation of the
mean, maximum, minimum, median and percentage values. The Student t test, or the
non-parametric Mann-Whitney test where appropriate, was employed to compare two
independent groups with respect to the variable of interest. Comparison between
categorical variables was performed using the &#x003c7;<sup>2</sup> test or the
Fisher exact test. The significance of differences was established at the 5%
probability (<italic>P</italic> &#x0003c;0.05) level. Pearson's correlation
coefficient was used to evaluate the relationship between two variables of
interest. All analyses were performed using SPSS software version 21.0 (IBM,
Armonk, NY, USA).</p></sec></sec><sec sec-type="results"><title>RESULTS</title><sec><title>Characteristics of Donors</title><p>The majority of donors (74.4%) were males with mean age around 30 years (range 18
- 54 years). Traumatic brain injury (TBI) caused by a traffic accident was the
most common cause of death, followed by hemorrhagic stroke, TBI caused by a
gunshot wound, and ischemic stroke. Only 7% of donors had a history of
alcoholism and 2.3% of tobacco dependence. Additionally, 95% of donors received
hormonal therapy including enteral administration of levothyroxine (1.5
&#x000b5;g/kg) and intravenous administration of methylprednisolone (15 mg/kg)
every 24 h immediately after diagnosis of brain death (<xref ref-type="table" rid="t1">Table 1</xref>).</p><table-wrap id="t1" orientation="portrait" position="float"><label>Table 1</label><caption><p>Characteristics of donors and recipients, and preoperative manometric
data of recipients.</p></caption><table frame="box" rules="all"><colgroup span="1"><col width="50%" span="1"/><col width="25%" span="1"/><col width="25%" span="1"/></colgroup><tbody><tr style="border-right:hidden;border-left:hidden"><td rowspan="1" colspan="1">Variable</td><td align="center" rowspan="1" colspan="1">Recipients (N = 43)</td><td align="center" rowspan="1" colspan="1">Donors (N = 43)</td></tr><tr style="border-right:hidden;border-left:hidden"><td rowspan="1" colspan="1">Male [<italic>n</italic> (%)]</td><td align="center" rowspan="1" colspan="1">24 (55.8)</td><td align="center" rowspan="1" colspan="1">32 (74.4)</td></tr><tr style="border-right:hidden;border-left:hidden"><td rowspan="1" colspan="1">Age (years)</td><td align="center" rowspan="1" colspan="1">44.8&#x000b1;12.0</td><td align="center" rowspan="1" colspan="1">30.1&#x000b1;10.4</td></tr><tr style="border-right:hidden;border-left:hidden"><td rowspan="1" colspan="1">Weight (kg)</td><td align="center" rowspan="1" colspan="1">62.3&#x000b1;8.9</td><td align="center" rowspan="1" colspan="1">69.7&#x000b1;10.7</td></tr><tr style="border-right:hidden;border-left:hidden"><td rowspan="1" colspan="1">Height (m)</td><td align="center" rowspan="1" colspan="1">1.64&#x000b1;0.9</td><td align="center" rowspan="1" colspan="1">1.7&#x000b1;0.1</td></tr><tr style="border-right:hidden;border-left:hidden"><td rowspan="1" colspan="1">Body mass index (kg/m<sup>2</sup>)</td><td align="center" rowspan="1" colspan="1">22.3&#x000b1;2.7</td><td align="center" rowspan="1" colspan="1">23.6&#x000b1;2.4</td></tr><tr style="border-right:hidden;border-left:hidden"><td rowspan="1" colspan="1">Body surface area (m<sup>2</sup>)</td><td align="center" rowspan="1" colspan="1">1.7&#x000b1;0.2</td><td align="center" rowspan="1" colspan="1">1.8&#x000b1;0.2</td></tr><tr style="border-right:hidden;border-left:hidden"><td rowspan="1" colspan="1">PVR (Wood units; before/after sodium nitroprusside)</td><td align="center" rowspan="1" colspan="1">3.2&#x000b1;2.3/2.6&#x000b1;1.3</td><td align="center" rowspan="1" colspan="1">-</td></tr><tr style="border-right:hidden;border-left:hidden"><td rowspan="1" colspan="1">Cardiac output (L/min)</td><td align="center" rowspan="1" colspan="1">3.1&#x000b1;0.9</td><td align="center" rowspan="1" colspan="1">-</td></tr><tr style="border-right:hidden;border-left:hidden"><td rowspan="1" colspan="1">Cardiac index (L/min/m<sup>2</sup>)</td><td align="center" rowspan="1" colspan="1">1.8&#x000b1;1.4</td><td align="center" rowspan="1" colspan="1">-</td></tr><tr style="border-right:hidden;border-left:hidden"><td rowspan="1" colspan="1">TPG (mmHg; before/after sodium nitroprusside)</td><td align="center" rowspan="1" colspan="1">8.2&#x000b1;4.8</td><td align="center" rowspan="1" colspan="1">-</td></tr><tr style="border-right:hidden;border-left:hidden"><td rowspan="1" colspan="1">Eurotransplant heart donor score (mean)</td><td align="center" rowspan="1" colspan="1">-</td><td align="center" rowspan="1" colspan="1">13</td></tr><tr style="border-right:hidden;border-left:hidden"><td rowspan="1" colspan="1">Hospitalization time (days; before transplant)</td><td align="center" rowspan="1" colspan="1">22.4&#x000b1;14.4</td><td align="center" rowspan="1" colspan="1">6.6&#x000b1;4.7</td></tr><tr style="border-right:hidden;border-left:hidden"><td rowspan="1" colspan="1">Use of intra-aortic balloon (<italic>n</italic>)</td><td align="center" rowspan="1" colspan="1">4</td><td align="center" rowspan="1" colspan="1">-</td></tr><tr style="border-right:hidden;border-left:hidden"><td colspan="3" rowspan="1"> Cause of encephalic death
[<italic>n</italic> (%)]</td></tr><tr style="border-right:hidden;border-left:hidden"><td rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;Traumatic brain injury
(motorcycle/car accident)</td><td align="center" rowspan="1" colspan="1">-</td><td align="center" rowspan="1" colspan="1">17 (39.5)</td></tr><tr style="border-right:hidden;border-left:hidden"><td rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;Hemorrhagic stroke</td><td align="center" rowspan="1" colspan="1">-</td><td align="center" rowspan="1" colspan="1">13 (30.2)</td></tr><tr style="border-right:hidden;border-left:hidden"><td rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;Traumatic brain injury (firearm
projectile)</td><td align="center" rowspan="1" colspan="1">-</td><td align="center" rowspan="1" colspan="1">8 (18.6)</td></tr><tr style="border-right:hidden;border-left:hidden"><td rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;Ischemic stroke</td><td align="center" rowspan="1" colspan="1">-</td><td align="center" rowspan="1" colspan="1">2 (4.7)</td></tr><tr style="border-right:hidden;border-left:hidden"><td rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;Other</td><td align="center" rowspan="1" colspan="1">-</td><td align="center" rowspan="1" colspan="1">3 (7.0)</td></tr><tr style="border-right:hidden;border-left:hidden"><td rowspan="1" colspan="1">Alcoholism</td><td align="center" rowspan="1" colspan="1">-</td><td align="center" rowspan="1" colspan="1">3 (7.0)</td></tr><tr style="border-right:hidden;border-left:hidden"><td rowspan="1" colspan="1">Tobacco addiction</td><td align="center" rowspan="1" colspan="1">-</td><td align="center" rowspan="1" colspan="1">1 (2.3)</td></tr><tr style="border-right:hidden;border-left:hidden"><td colspan="3" rowspan="1"> Hormonal therapy [<italic>n</italic>
(%)]</td></tr><tr style="border-right:hidden;border-left:hidden"><td rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;Levothyroxine</td><td align="center" rowspan="1" colspan="1">-</td><td align="center" rowspan="1" colspan="1">41 (95.3)</td></tr><tr style="border-right:hidden;border-left:hidden"><td rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;Methylprednisolone</td><td align="center" rowspan="1" colspan="1">-</td><td align="center" rowspan="1" colspan="1">41 (95.3)</td></tr><tr style="border-right:hidden;border-left:hidden"><td rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;Insulin</td><td align="center" rowspan="1" colspan="1">-</td><td align="center" rowspan="1" colspan="1">34 (79.1)</td></tr><tr style="border-right:hidden;border-left:hidden"><td rowspan="1" colspan="1">Left ventricular ejection fraction (%)</td><td align="center" rowspan="1" colspan="1"><xref ref-type="table-fn" rid="TFN2">*</xref>
65.4&#x000b1;11.9</td><td align="center" rowspan="1" colspan="1">66.2&#x000b1;6.2</td></tr><tr style="border-right:hidden;border-left:hidden"><td colspan="3" rowspan="1"> Etiology of cardiomyopathy [n
(%)]</td></tr><tr style="border-right:hidden;border-left:hidden"><td rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;Chagas disease</td><td align="center" rowspan="1" colspan="1">20 (46.5)</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td></tr><tr style="border-right:hidden;border-left:hidden"><td rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;Ischemia</td><td align="center" rowspan="1" colspan="1">10 (23.2)</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td></tr><tr style="border-right:hidden;border-left:hidden"><td rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;Idiopathy</td><td align="center" rowspan="1" colspan="1">7 (16.2)</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td></tr><tr style="border-right:hidden;border-left:hidden"><td rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;Valve diseases</td><td align="center" rowspan="1" colspan="1">2 (4.6)</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td></tr><tr style="border-right:hidden;border-left:hidden"><td rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;Other</td><td align="center" rowspan="1" colspan="1">4 (9.2)</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td></tr></tbody></table><table-wrap-foot><fn id="TFN1"><p>PVR=pulmonary vascular resistance; TPG=transpulmonary pressure
gradient</p></fn><fn id="TFN2"><label>*</label><p>After transplant</p></fn></table-wrap-foot></table-wrap><p>At the initiation of harvesting, 69.8% of donors exhibited mean arterial pressure
in the range 60 to 80 mmHg, while 16.3% presented pressure above 80 mmHg.
Furthermore, at the start of harvesting, 44.2% of the donors required more than
40% FiO<sub>2</sub> in the mechanical ventilator to maintain adequate arterial
oxygen supply (&#x02265; 90%) (<xref ref-type="table" rid="t2">Table
2</xref>).</p><table-wrap id="t2" orientation="portrait" position="float"><label>Table 2</label><caption><p>Clinical characteristics of donors at various stages during transplant
procedure.</p></caption><table frame="box" rules="all"><colgroup span="1"><col width="75%" span="1"/><col width="25%" span="1"/></colgroup><thead><tr style="border-right:hidden;border-left:hidden"><th align="center" rowspan="1" colspan="1">Variable</th><th align="center" rowspan="1" colspan="1"><italic>n</italic> (%)</th></tr></thead><tbody><tr style="border-right:hidden;border-left:hidden"><td rowspan="1" colspan="1">Mean arterial pressure 48 h prior to harvesting (mmHg)</td><td rowspan="1" colspan="1">&#x000a0;</td></tr><tr style="border-right:hidden;border-left:hidden"><td rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;40-59</td><td align="center" rowspan="1" colspan="1">5 (11.6)</td></tr><tr style="border-right:hidden;border-left:hidden"><td rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;60-80</td><td align="center" rowspan="1" colspan="1">31 (72.0)</td></tr><tr style="border-right:hidden;border-left:hidden"><td rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x0003e;80</td><td align="center" rowspan="1" colspan="1">7 (16.3)</td></tr><tr style="border-right:hidden;border-left:hidden"><td rowspan="1" colspan="1">Mean arterial pressure at initiation of harvesting (mmHg)</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td></tr><tr style="border-right:hidden;border-left:hidden"><td rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;40-59</td><td align="center" rowspan="1" colspan="1">6 (13.9)</td></tr><tr style="border-right:hidden;border-left:hidden"><td rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;60-80</td><td align="center" rowspan="1" colspan="1">30 (69.8)</td></tr><tr style="border-right:hidden;border-left:hidden"><td rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x0003e;80</td><td align="center" rowspan="1" colspan="1">7 (16.3)</td></tr><tr style="border-right:hidden;border-left:hidden"><td rowspan="1" colspan="1">Mechanical ventilation - FiO<sub>2</sub> 48 h prior to
harvesting (%)</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td></tr><tr style="border-right:hidden;border-left:hidden"><td rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;=40</td><td align="center" rowspan="1" colspan="1">32 (74.4)</td></tr><tr style="border-right:hidden;border-left:hidden"><td rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;41-60</td><td align="center" rowspan="1" colspan="1">5 (11.6)</td></tr><tr style="border-right:hidden;border-left:hidden"><td rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;61-80</td><td align="center" rowspan="1" colspan="1">4 (9.3)</td></tr><tr style="border-right:hidden;border-left:hidden"><td rowspan="1" colspan="1">Mechanical ventilation - FiO<sub>2</sub> at initiation of
harvesting (%)</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td></tr><tr style="border-right:hidden;border-left:hidden"><td rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;=40</td><td align="center" rowspan="1" colspan="1">23 (53.5)</td></tr><tr style="border-right:hidden;border-left:hidden"><td rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;41-60</td><td align="center" rowspan="1" colspan="1">7 (16.3)</td></tr><tr style="border-right:hidden;border-left:hidden"><td rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;61-80</td><td align="center" rowspan="1" colspan="1">12 (27.9)</td></tr><tr style="border-right:hidden;border-left:hidden"><td rowspan="1" colspan="1">Use of inotropic agents at admission</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td></tr><tr style="border-right:hidden;border-left:hidden"><td rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;Noradrenaline</td><td align="center" rowspan="1" colspan="1">31 (72.1)</td></tr><tr style="border-right:hidden;border-left:hidden"><td rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;Dobutamine</td><td align="center" rowspan="1" colspan="1">1 (2.3)</td></tr><tr style="border-right:hidden;border-left:hidden"><td rowspan="1" colspan="1">Use of inotrope/vasodilator immediately before harvesting</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td></tr><tr style="border-right:hidden;border-left:hidden"><td rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;Noradrenaline</td><td align="center" rowspan="1" colspan="1">24 (55.8)</td></tr><tr style="border-right:hidden;border-left:hidden"><td rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;Sodium nitroprusside</td><td align="center" rowspan="1" colspan="1">2 (4.7)</td></tr></tbody></table><table-wrap-foot><fn id="TFN3"><p>FiO<sub>2</sub>=fraction of inspired oxygen</p></fn></table-wrap-foot></table-wrap><p>The majority of donors (89.4%) received noradrenaline at some stage during
hospitalization (<xref ref-type="fig" rid="f1">Figure 1</xref>). Relatively low
doses of noradrenaline (&#x02264; 0.23 &#x000b5;g/kg/min) were administered during
hospitalization to most of the donors (54.3%), while 28.1% received moderate
doses (&#x0003e; 0.23 to &#x02264; 0.46 &#x000b5;g/kg/min), 7% required high doses
(&#x0003e; 0.46 &#x000b5;g/kg/min), and 10.6% did not receive noradrenaline.
Independent of dose, the highest frequency of administration of noradrenaline
(72.1%) was at the time of admission to hospital, while the use of this
inotropic agent was much less frequent (55.5%) immediately before surgery,
particularly during preparation of the patient for harvesting (administration of
hormone therapy and adjustment of clinical management).</p><p><fig id="f1" orientation="portrait" position="float"><label>Fig. 1</label><caption><p>Frequency of donors who received inotropic support (noradrenaline) at
different stages during hospitalization.</p></caption><graphic xlink:href="rbccv-31-02-0089-g01"/></fig></p><p>The left VEF values of the donors varied between 52% and 80% (mean
66.2&#x000b1;6.2%) with a median value of 65%, and only three (6.9%) donors
exhibited left VEF values below the optimum level of &#x02265; 60%.</p></sec><sec><title>Characteristics of Recipients</title><p>Of the 43 recipients, 55.8% were males with mean age around 45 years, mean weight
of 62.3 kg and mean height of 1.64 m (<xref ref-type="table" rid="t1">Table
1</xref>). The pulmonary vascular resistance (PVR) values before and after
administration of sodium nitroprusside were 3.2 and 2.6 Wood units,
respectively, whereas the mean hemoglobin concentration was 12.5 g/dL at the
time of pre-transplant cardiac manometry. The most prevalent etiologies of
myocardiopathy among the recipients were Chagas disease (46.5%) followed by
ischemia and idiopathic causes. Only one patient underwent retransplant by
virtue of cardiac allograft vasculopathy that had evolved over a period of 10
years (<xref ref-type="table" rid="t1">Table 1</xref>).</p><p>The majority of recipients (76.7%) were hospitalized priority patients who had
received continuous administration of dobutamine to preserve hemodynamic
stability. Ten (39.3%) of these patients (representing of 23.2% of the total
number) were in critical state in the ICU and had received high doses of
dobutamine or noradrenaline combined with dobutamine to maintain a minimally
adequate cardiac output. Despite the gravity of these patients, only three
(6.9%) had endotracheal intubation while in the ICU at the time of
transplant.</p><p>In the post-transplant period, four patients required the insertion of an
intra-aortic balloon pump. In one case the device was considered necessary
because of the development of PGD with left ventricular dysfunction prevalence,
while three patients died due to secondary graft dysfuntion. None of these four
patients had isolated right ventricular dysfunction. The left VEF values of the
recipients in the first week after transplant varied between 20% and 85% (mean
65.4&#x000b1;11.9%) with a median value of 69%. Only eight recipients (18.6%)
presented abnormally low VEF values. The vast majority of recipients had
received noradrenaline and/or dobutamine during anesthesia induction and after
withdrawal of CPB (<xref ref-type="table" rid="t3">Table 3</xref>). During
transplant, the mean CPB time was 121 min, whereas the mean times of ischemia of
the transplanted organ and aortic clamping were 126 and 86 min,
respectively.</p><table-wrap id="t3" orientation="portrait" position="float"><label>Table 3</label><caption><p>Clinical characteristics of recipients at various stages during
transplant procedure.</p></caption><table frame="box" rules="all"><colgroup span="1"><col width="75%" span="1"/><col width="25%" span="1"/></colgroup><thead><tr style="border-right:hidden;border-left:hidden"><th align="center" rowspan="1" colspan="1">Variable</th><th align="center" rowspan="1" colspan="1"><italic>n</italic> (%)</th></tr></thead><tbody><tr style="border-right:hidden;border-left:hidden"><td rowspan="1" colspan="1">Use of inotrope/vasodilator at anesthesia induction</td><td rowspan="1" colspan="1">&#x000a0;</td></tr><tr style="border-right:hidden;border-left:hidden"><td rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;Noradrenaline</td><td align="center" rowspan="1" colspan="1">13 (30.2)</td></tr><tr style="border-right:hidden;border-left:hidden"><td rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;Dobutamine</td><td align="center" rowspan="1" colspan="1">33 (76.7)</td></tr><tr style="border-right:hidden;border-left:hidden"><td rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;Dopamine</td><td align="center" rowspan="1" colspan="1">1 (2.3)</td></tr><tr style="border-right:hidden;border-left:hidden"><td rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;Adrenaline</td><td align="center" rowspan="1" colspan="1">1 (2.3)</td></tr><tr style="border-right:hidden;border-left:hidden"><td rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;Sodium nitroprusside</td><td align="center" rowspan="1" colspan="1">3 (7.0)</td></tr><tr style="border-right:hidden;border-left:hidden"><td rowspan="1" colspan="1">Use of inotrope/vasodilator after withdrawal of CPB</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td></tr><tr style="border-right:hidden;border-left:hidden"><td rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;Noradrenaline</td><td align="center" rowspan="1" colspan="1">15 (34.9)</td></tr><tr style="border-right:hidden;border-left:hidden"><td rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;Dobutamine</td><td align="center" rowspan="1" colspan="1">42 (97.7)</td></tr><tr style="border-right:hidden;border-left:hidden"><td rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;Adrenaline</td><td align="center" rowspan="1" colspan="1">3 (7.0)</td></tr><tr style="border-right:hidden;border-left:hidden"><td rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;Sodium nitroprusside</td><td align="center" rowspan="1" colspan="1">14 (32.6)</td></tr><tr style="border-right:hidden;border-left:hidden"><td rowspan="1" colspan="1">Use of inotrope/vasodilator 24 h after surgery</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td></tr><tr style="border-right:hidden;border-left:hidden"><td rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;Noradrenaline</td><td align="center" rowspan="1" colspan="1">16 (37.2)</td></tr><tr style="border-right:hidden;border-left:hidden"><td rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;Dobutamine</td><td align="center" rowspan="1" colspan="1">38 (88.4)</td></tr><tr style="border-right:hidden;border-left:hidden"><td rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;Dopamine</td><td align="center" rowspan="1" colspan="1">1 (2.3)</td></tr><tr style="border-right:hidden;border-left:hidden"><td rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;Sodium nitroprusside</td><td align="center" rowspan="1" colspan="1">6 (14)</td></tr><tr style="border-right:hidden;border-left:hidden"><td rowspan="1" colspan="1">Use of inotrope/vasodilator 1 week after surgery</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td></tr><tr style="border-right:hidden;border-left:hidden"><td rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;Noradrenaline</td><td align="center" rowspan="1" colspan="1">1 (2.3)</td></tr><tr style="border-right:hidden;border-left:hidden"><td rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;Dobutamine</td><td align="center" rowspan="1" colspan="1">15 (34.9)</td></tr><tr style="border-right:hidden;border-left:hidden"><td rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;Dopamine</td><td align="center" rowspan="1" colspan="1">1 (2.3)</td></tr><tr style="border-right:hidden;border-left:hidden"><td rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;Sodium nitroprusside</td><td align="center" rowspan="1" colspan="1">1 (2.3)</td></tr><tr style="border-right:hidden;border-left:hidden"><td rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;Operating time (h)</td><td align="center" rowspan="1" colspan="1">5.0&#x000b1;1.3</td></tr><tr style="border-right:hidden;border-left:hidden"><td rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;CPB time (h)</td><td align="center" rowspan="1" colspan="1">2.0&#x000b1;0.7</td></tr><tr style="border-right:hidden;border-left:hidden"><td rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;Aortic clamping time (h)</td><td align="center" rowspan="1" colspan="1">1.4&#x000b1;0.3</td></tr><tr style="border-right:hidden;border-left:hidden"><td rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;Ischemia time (h)</td><td align="center" rowspan="1" colspan="1">2.1&#x000b1;0.5</td></tr><tr style="border-right:hidden;border-left:hidden"><td rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;ICU time (days)</td><td align="center" rowspan="1" colspan="1">6.9&#x000b1;5.6</td></tr></tbody></table><table-wrap-foot><fn id="TFN4"><p>CPB=cardiopulmonary bypass; ICU=intensive care unit</p></fn></table-wrap-foot></table-wrap></sec><sec><title>Statistical Analysis of Recipient Outcomes</title><p>The recipients with moderate to severe left ventricular dysfunction (VEF &#x02264;
45%) on echocardiography after transplant had received organs from donors who
were significantly older CPB=cardiopulmonary bypass; ICU=intensive care unit
(<italic>P</italic> =0.020; <xref ref-type="table" rid="t4">Table 4</xref>).
Furthermore, the recipients of organs from donors who required moderate to high
doses of noradrenaline (&#x0003e; 0.23 &#x000b5;g/kg/min) before harvesting exhibited
significantly lower VEF values after transplant (<italic>P</italic> =0.002).</p><table-wrap id="t4" orientation="portrait" position="float"><label>Table 4</label><caption><p>Association between age of donor and right and left ventricular
dysfunction in recipient after heart transplant</p></caption><table frame="box" rules="all"><colgroup span="1"><col width="45%" span="1"/><col width="35%" span="1"/><col width="20%" span="1"/></colgroup><thead><tr style="border-right:hidden;border-left:hidden"><th align="center" rowspan="1" colspan="1">Outcome of recipient</th><th align="center" rowspan="1" colspan="1">Age of donor</th><th align="center" rowspan="1" colspan="1"><italic>P</italic> value</th></tr></thead><tbody><tr style="border-right:hidden;border-left:hidden"><td rowspan="1" colspan="1">Right ventricular dysfunction</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td></tr><tr style="border-right:hidden;border-left:hidden"><td rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;Absent/mild</td><td align="center" rowspan="1" colspan="1">29.47 + 10.79 (28.50)</td><td align="center" rowspan="1" colspan="1">0.498</td></tr><tr style="border-right:hidden;border-left:hidden"><td rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;Moderate/severe</td><td align="center" rowspan="1" colspan="1">31.55 + 10.21 (33.00)</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td></tr><tr style="border-right:hidden;border-left:hidden"><td rowspan="1" colspan="1">Left ventricular dysfunction</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td></tr><tr style="border-right:hidden;border-left:hidden"><td rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;Absent/mild (&#x0003e; 45%)</td><td align="center" rowspan="1" colspan="1">28.68 + 9.94 (27.50)</td><td align="center" rowspan="1" colspan="1">0.020 <xref ref-type="table-fn" rid="TFN6">*</xref></td></tr><tr style="border-right:hidden;border-left:hidden"><td rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;Moderate /severe (&#x0003c; 45%)</td><td align="center" rowspan="1" colspan="1">39.50 + 9.65 (39.00)</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td></tr><tr style="border-right:hidden;border-left:hidden"><td rowspan="1" colspan="1">Mortality</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td></tr><tr style="border-right:hidden;border-left:hidden"><td rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;No</td><td align="center" rowspan="1" colspan="1">29.42 + 10.47 (28.50)</td><td align="center" rowspan="1" colspan="1">0.151</td></tr><tr style="border-right:hidden;border-left:hidden"><td rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;Yes</td><td align="center" rowspan="1" colspan="1">36.50 + 8.58 (38.00)</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td></tr></tbody></table><table-wrap-foot><fn id="TFN5"><p>Data presented as mean + standard deviation (median)</p></fn><fn id="TFN6"><label>*</label><p>Mean values significantly different (<italic>P</italic>&#x0003c;0.05)
according to Mann-Whitney test.</p></fn></table-wrap-foot></table-wrap><p>As shown in <xref ref-type="table" rid="t5">Table 5</xref>, when plasma levels of
sTNFR1 and sTNFR2 in donors were significantly higher (<italic>P</italic> =0.014
and <italic>P</italic> =0.030, respectively), the corresponding recipients
remained in ICU for shorter periods (&#x02264; 5 days). Similarly, when IL-6 was
significantly higher (<italic>P</italic> =0.029) in donors, the hospitalization
times of recipients were shorter (&#x02264; 25 days). Furthermore, when donors
exhibited significantly lower plasma concentrations of sTNFR2 and IL-6
(<italic>P</italic> =0.028 and <italic>P</italic> =0.001, respectively), the
recipients required moderate/high doses of noradrenaline (&#x0003e; 0.23
&#x000b5;g/kg/min) after being weaned off CPB and during the postoperative
period.</p><table-wrap id="t5" orientation="portrait" position="float"><label>Table 5</label><caption><p>Outcomes of recipients distributed according to the levels of potential
cardiac markers in donors.</p></caption><table frame="box" rules="all"><colgroup span="1"><col width="10%" span="1"/><col width="15%" span="1"/><col width="15%" span="1"/><col width="15%" span="1"/><col width="15%" span="1"/><col width="15%" span="1"/><col width="15%" span="1"/></colgroup><tbody><tr style="border-right:hidden;border-left:hidden"><td rowspan="4" align="center" colspan="1">Potential biomarker in donors</td><td colspan="6" align="center" rowspan="1"> Outcomes of recipients</td></tr><tr style="border-right:hidden;border-left:hidden"><td colspan="2" align="center" rowspan="1">ICU time</td><td colspan="2" align="center" rowspan="1">Hospitalization time</td><td colspan="2" align="center" rowspan="1">Moderate/high levels of noradrenaline
(&#x0003e; 0.23 &#x000b5;g/kg/min)</td></tr><tr style="border-right:hidden;border-left:hidden"><td align="center" rowspan="1" colspan="1">&#x02264; 5 days (n=24)</td><td align="center" rowspan="1" colspan="1">&#x0003e; 5 days (n=15)</td><td align="center" rowspan="1" colspan="1">&#x02264; 25 days (n=32)</td><td align="center" rowspan="1" colspan="1">&#x0003e; 25 days (n=10)</td><td align="center" rowspan="1" colspan="1">No (n=27)</td><td align="center" rowspan="1" colspan="1">Yes (n=16)</td></tr><tr style="border-right:hidden;border-left:hidden"><td colspan="2" align="center" rowspan="1"><italic>P</italic>=0.014 <xref ref-type="table-fn" rid="TFN8">*</xref></td><td colspan="2" align="center" rowspan="1"><italic>P</italic>=0.679</td><td colspan="2" align="center" rowspan="1"><italic>P</italic>=0.108</td></tr><tr style="border-right:hidden;border-left:hidden"><td rowspan="2" align="left" colspan="1">sTNFR2 pg/mL</td><td align="center" rowspan="1" colspan="1">6218.47+2436.51 (5555.84)</td><td align="center" rowspan="1" colspan="1">5002.76+2002.69 (4469.48)</td><td align="center" rowspan="1" colspan="1">5952.36+434.11 (5313.87)</td><td align="center" rowspan="1" colspan="1">5594.06+2345.63 (4916.84)</td><td align="center" rowspan="1" colspan="1">6422.48+2342.89 (5537.89)</td><td align="center" rowspan="1" colspan="1">4913.71+2139.24 (4469.48)</td></tr><tr style="border-right:hidden;border-left:hidden"><td colspan="2" align="center" rowspan="1"><italic>P</italic>=0.030 <xref ref-type="table-fn" rid="TFN8">*</xref></td><td colspan="2" align="center" rowspan="1"><italic>P</italic>=0.545</td><td colspan="2" align="center" rowspan="1"><italic>P=0.028 <xref ref-type="table-fn" rid="TFN8">*</xref></italic></td></tr><tr style="border-right:hidden;border-left:hidden"><td rowspan="2" align="left" colspan="1">IL-6 pg/mL</td><td align="center" rowspan="1" colspan="1">239.84+250.16 (158.10)</td><td align="center" rowspan="1" colspan="1">117.97+141.61 (87.64)</td><td align="center" rowspan="1" colspan="1">209.78+205.96 (158.10)</td><td align="center" rowspan="1" colspan="1">129.61+237.87 (62.53)</td><td align="center" rowspan="1" colspan="1">254.65+238.06 (164.10)</td><td align="center" rowspan="1" colspan="1">80.41+80.04 (60.99)</td></tr><tr style="border-right:hidden;border-left:hidden"><td colspan="2" align="center" rowspan="1"><italic>P</italic>=0.053</td><td colspan="2" align="center" rowspan="1"><italic>P</italic>=0.029 <xref ref-type="table-fn" rid="TFN8">*</xref></td><td colspan="2" align="center" rowspan="1"><italic>P</italic>=0.001 <xref ref-type="table-fn" rid="TFN8">*</xref></td></tr><tr style="border-right:hidden;border-left:hidden"><td rowspan="2" align="left" colspan="1">IL-10 pg/mL</td><td align="center" rowspan="1" colspan="1">243.61+273.32 (133.45)</td><td align="center" rowspan="1" colspan="1">111.45+173.68 (31.08)</td><td align="center" rowspan="1" colspan="1">234.50+258.01 (133.45)</td><td align="center" rowspan="1" colspan="1">64.93+99.15 (14.95)</td><td align="center" rowspan="1" colspan="1">251.61+267.89 (198.25)</td><td align="center" rowspan="1" colspan="1">101.27+137.26 (47.42)</td></tr><tr style="border-right:hidden;border-left:hidden"><td colspan="2" align="center" rowspan="1"><italic>P</italic>=0.078</td><td colspan="2" align="center" rowspan="1"><italic>P</italic>=0.037 <xref ref-type="table-fn" rid="TFN8">*</xref></td><td colspan="2" align="center" rowspan="1">P=0.079</td></tr><tr style="border-right:hidden;border-left:hidden"><td rowspan="2" align="left" colspan="1">MCP1 &#x000b5;g/mL</td><td align="center" rowspan="1" colspan="1">83.37+70.47 (61.06)</td><td align="center" rowspan="1" colspan="1">64.53+69.43 (35.41)</td><td align="center" rowspan="1" colspan="1">82.89+71.06 (61.06)</td><td align="center" rowspan="1" colspan="1">70.73+67.34 (61.35)</td><td align="center" rowspan="1" colspan="1">91.85+68.56 (64.89)</td><td align="center" rowspan="1" colspan="1">57.41+65.71 (24.15)</td></tr><tr style="border-right:hidden;border-left:hidden"><td colspan="2" align="center" rowspan="1"><italic>P</italic>=0.528</td><td colspan="2" align="center" rowspan="1"><italic>P</italic>=0.727</td><td colspan="2" align="center" rowspan="1"><italic>P</italic>=0.092</td></tr></tbody></table><table-wrap-foot><fn id="TFN7"><p>sTNFR=soluble tumor necrosis factor receptor; IL=interleukin;
MCP=monocyte chemoattractant protein 1; CRP=C-reactive protein;
cTnI=cardiac troponin I. Data presented as mean + standard deviation
(median).</p></fn><fn id="TFN8"><label>*</label><p>Mean values significantly different (<italic>P</italic>&#x0003c;0.05)
according to Mann-Whitney test.</p></fn></table-wrap-foot></table-wrap><p>Recipients of organs from donors who had received moderate/high doses of
noradrenaline (&#x0003e; 0.23 &#x000b5;g/kg/min) during hospitalization remained
connected to the CPB pump for significantly longer periods (<italic>P</italic>
=0.039) in comparison with those that had received organs from donors not been
medicated in this manner (<xref ref-type="table" rid="t6">Table 6</xref>).
Recipients presenting moderate/severe ventricular dysfunctions (left or right)
on echocardiography after transplant experienced significantly longer operating
and CPB times (<italic>P</italic> =0.038 and <italic>P</italic> =0.022,
respectively) compared with those who were not affected by PGD (<xref ref-type="table" rid="t6">Table 6</xref>).</p><table-wrap id="t6" orientation="portrait" position="float"><label>Table 6</label><caption><p>Outcomes of recipients distributed according to clinical characteristics
of donors and recipients.</p></caption><table frame="box" rules="all"><colgroup span="1"><col width="24%" span="1"/><col width="19%" span="1"/><col width="19%" span="1"/><col width="19%" span="1"/><col width="19%" span="1"/></colgroup><tbody><tr style="border-right:hidden;border-left:hidden"><td rowspan="3" align="left" colspan="1">Outcomes of recipients</td><td colspan="2" align="center" rowspan="1">Donors</td><td colspan="2" align="center" rowspan="1">Recipients</td></tr><tr style="border-right:hidden;border-left:hidden"><td colspan="2" align="center" rowspan="1">Required moderate/high levels of
noradrenaline (&#x0003e; 0.23 &#x000b5;g/kg/min)</td><td colspan="2" align="center" rowspan="1">Postoperative PGD on echo</td></tr><tr style="border-right:hidden;border-left:hidden"><td align="center" rowspan="1" colspan="1">No</td><td align="center" rowspan="1" colspan="1">Yes</td><td align="center" rowspan="1" colspan="1">No</td><td align="center" rowspan="1" colspan="1">Yes</td></tr><tr style="border-right:hidden;border-left:hidden"><td rowspan="2" align="left" colspan="1">Operating time (h)</td><td align="center" rowspan="1" colspan="1">4.86 + 1.23 (4.58)</td><td align="center" rowspan="1" colspan="1">5.38 + 1.32 (5.50)</td><td align="center" rowspan="1" colspan="1">4.76 + 1.29 (4.00)</td><td align="center" rowspan="1" colspan="1">5.58 + 1.08 (5.75)</td></tr><tr style="border-right:hidden;border-left:hidden"><td colspan="2" align="center" rowspan="1"><italic>P</italic> = 0.228</td><td colspan="2" align="center" rowspan="1"><italic>P</italic> = 0.038 <xref ref-type="table-fn" rid="TFN11">*</xref></td></tr><tr style="border-right:hidden;border-left:hidden"><td rowspan="2" align="left" colspan="1">CPB time (h)</td><td align="center" rowspan="1" colspan="1">1.87 + 0.53 (1.70)</td><td align="center" rowspan="1" colspan="1">2.34 + 1.02 (2.09)</td><td align="center" rowspan="1" colspan="1">1.83 + 0.49 (1.70)</td><td align="center" rowspan="1" colspan="1">2.49 + 1.02 (2.13)</td></tr><tr style="border-right:hidden;border-left:hidden"><td colspan="2" align="center" rowspan="1"><italic>P</italic> = 0.039 <xref ref-type="table-fn" rid="TFN11">*</xref></td><td colspan="2" align="center" rowspan="1"><italic>P</italic> = 0.022 <xref ref-type="table-fn" rid="TFN11">*</xref></td></tr><tr style="border-right:hidden;border-left:hidden"><td rowspan="2" align="left" colspan="1">Aortic clamping time (h)</td><td align="center" rowspan="1" colspan="1">1.42 + 0.27 (1.28)</td><td align="center" rowspan="1" colspan="1">1.50 + 0.29 (1.49)</td><td align="center" rowspan="1" colspan="1">1.39 + 0.27 (1.28)</td><td align="center" rowspan="1" colspan="1">1.54 + 0.28 (1.58)</td></tr><tr style="border-right:hidden;border-left:hidden"><td colspan="2" align="center" rowspan="1"><italic>P</italic> = 0.248</td><td colspan="2" align="center" rowspan="1"><italic>P</italic> = 0.141</td></tr><tr style="border-right:hidden;border-left:hidden"><td rowspan="2" align="left" colspan="1">Ischemia time (h)</td><td align="center" rowspan="1" colspan="1">2.02 + 0.52 (1.87)</td><td align="center" rowspan="1" colspan="1">2.24 + 0.46 (2.38)</td><td align="center" rowspan="1" colspan="1">2.09 + 0.56 (1.96)</td><td align="center" rowspan="1" colspan="1">2.14 + 0.41 (2.00)</td></tr><tr style="border-right:hidden;border-left:hidden"><td colspan="2" align="center" rowspan="1"><italic>P</italic> = 0.067</td><td colspan="2" align="center" rowspan="1"><italic>P</italic> = 0.512</td></tr><tr style="border-right:hidden;border-left:hidden"><td rowspan="2" align="left" colspan="1">ICU time (days)</td><td align="center" rowspan="1" colspan="1">6.81 + 5.89 (5.00)</td><td align="center" rowspan="1" colspan="1">7.00 + 5.00 (5.00)</td><td align="center" rowspan="1" colspan="1">6.25 + 4.91 (5.00)</td><td align="center" rowspan="1" colspan="1">8.60 + 7.15 (5.50)</td></tr><tr style="border-right:hidden;border-left:hidden"><td colspan="2" align="center" rowspan="1"><italic>P</italic> = 0.909</td><td colspan="2" align="center" rowspan="1"><italic>P</italic> = 0.349</td></tr><tr style="border-right:hidden;border-left:hidden"><td rowspan="2" align="left" colspan="1">Hospitalization time (days)</td><td align="center" rowspan="1" colspan="1">22.15 + 55.85 (15.00)</td><td align="center" rowspan="1" colspan="1">7.00 + 5.00 (19.50)</td><td align="center" rowspan="1" colspan="1">20.86 + 11.45 (15.00)</td><td align="center" rowspan="1" colspan="1">27.70 + 20.80 (19.50)</td></tr><tr style="border-right:hidden;border-left:hidden"><td colspan="2" align="center" rowspan="1"><italic>P</italic> = 0.314</td><td colspan="2" align="center" rowspan="1"><italic>P</italic> = 0.419</td></tr></tbody></table><table-wrap-foot><fn id="TFN10"><label/><p>PGD=primary graft dysfunction; CPB=cardiopulmonary bypass;
ICU=intensive care unit. Data presented as mean + standard deviation
(median)</p></fn><fn id="TFN11"><label>*</label><p>Mean values significantly different (<italic>P</italic>&#x0003c;0.05)
according to Mann-Whitney test.</p></fn></table-wrap-foot></table-wrap><p>Most of the recipients (79.2%) of organs from donors who had not received
noradrenaline or who had received at a low dose (&#x0003c; 0.23 &#x000b5;/kg/min)
remained in ICU for a maximum of five days, whereas the majority of patients
(66.7%) transplanted with organs from donors who had received moderate/high
doses of noradrenaline (&#x0003e; 0.23 &#x000b5;/kg/min) remained in ICU for more than
five days (<italic>P</italic> =0.004; <xref ref-type="table" rid="t7">Table
7</xref>).</p><table-wrap id="t7" orientation="portrait" position="float"><label>Table 7</label><caption><p>Outcomes of recipients distributed according to the doses of
noradrenaline administered to donors during hospitalization.</p></caption><table frame="box" rules="all"><colgroup span="1"><col width="40%" span="1"/><col width="30%" span="1"/><col width="30%" span="1"/></colgroup><thead><tr style="border-right:hidden;border-left:hidden"><th align="left" rowspan="2" colspan="1"> Outcomes of recipients</th><th align="left" colspan="2" rowspan="1">Donors requiring moderate/high levels
of noradrenaline (&#x0003e; 0.23 &#x000b5;g/ kg/min)</th></tr><tr style="border-right:hidden;border-left:hidden"><th rowspan="1" colspan="1">No [<italic>n</italic> (%)]</th><th rowspan="1" colspan="1">Yes [<italic>n</italic> (%)]</th></tr></thead><tbody><tr style="border-right:hidden;border-left:hidden"><td colspan="3" rowspan="1"> ICU time (days) <xref ref-type="table-fn" rid="TFN13">a</xref>
<sup>,</sup>
<xref ref-type="table-fn" rid="TFN15">c</xref></td></tr><tr style="border-right:hidden;border-left:hidden"><td rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x02264; 5</td><td rowspan="1" colspan="1">19 (79.2)</td><td rowspan="1" colspan="1">5 (33.3)</td></tr><tr style="border-right:hidden;border-left:hidden"><td rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x0003e; 5</td><td rowspan="1" colspan="1">5 (20.8)</td><td rowspan="1" colspan="1">10 (66.7)</td></tr><tr style="border-right:hidden;border-left:hidden"><td rowspan="1" colspan="1">&#x000a0;</td><td colspan="2" align="center" rowspan="1"><italic>P</italic>=0.004 <xref ref-type="table-fn" rid="TFN16">*</xref></td></tr><tr style="border-right:hidden;border-left:hidden"><td colspan="3" rowspan="1"> Hospitalization time (days) <xref ref-type="table-fn" rid="TFN14">b</xref>
<sup>,</sup>
<xref ref-type="table-fn" rid="TFN15">c</xref></td></tr><tr style="border-right:hidden;border-left:hidden"><td rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x02264; 25</td><td rowspan="1" colspan="1">21 (84.0)</td><td rowspan="1" colspan="1">8 (57.1)</td></tr><tr style="border-right:hidden;border-left:hidden"><td rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x0003e; 25</td><td rowspan="1" colspan="1">4 (16.0)</td><td rowspan="1" colspan="1">6 (42.9)</td></tr><tr style="border-right:hidden;border-left:hidden"><td rowspan="1" colspan="1">&#x000a0;</td><td colspan="2" align="center" rowspan="1"><italic>P</italic>=0.124</td></tr><tr style="border-right:hidden;border-left:hidden"><td colspan="3" rowspan="1"> Right ventricular dysfunction <xref ref-type="table-fn" rid="TFN14">b</xref>
<sup>,</sup>
<xref ref-type="table-fn" rid="TFN15">c</xref></td></tr><tr style="border-right:hidden;border-left:hidden"><td rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;Absent/mild</td><td rowspan="1" colspan="1">22 (84.6)</td><td rowspan="1" colspan="1">9 (56.2)</td></tr><tr style="border-right:hidden;border-left:hidden"><td rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;Moderate/severe</td><td rowspan="1" colspan="1">4 (15.4)</td><td rowspan="1" colspan="1">7 (43.8)</td></tr><tr style="border-right:hidden;border-left:hidden"><td rowspan="1" colspan="1">&#x000a0;</td><td colspan="2" align="center" rowspan="1"><italic>P</italic>=0.070</td></tr><tr style="border-right:hidden;border-left:hidden"><td colspan="3" rowspan="1">Left ventricular dysfunction <xref ref-type="table-fn" rid="TFN14">b</xref>
<sup>,</sup>
<xref ref-type="table-fn" rid="TFN15">c</xref></td></tr><tr style="border-right:hidden;border-left:hidden"><td rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;Absent/mild</td><td rowspan="1" colspan="1">23 (88.5)</td><td rowspan="1" colspan="1">12 (80.0)</td></tr><tr style="border-right:hidden;border-left:hidden"><td rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;Moderate/severe</td><td rowspan="1" colspan="1">3 (11.5)</td><td rowspan="1" colspan="1">3 (20.0)</td></tr><tr style="border-right:hidden;border-left:hidden"><td rowspan="1" colspan="1">&#x000a0;</td><td colspan="2" align="center" rowspan="1"><italic>P</italic>=0.651</td></tr><tr style="border-right:hidden;border-left:hidden"><td colspan="3" rowspan="1"> Mortality <xref ref-type="table-fn" rid="TFN14">b</xref></td></tr><tr style="border-right:hidden;border-left:hidden"><td rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;No</td><td rowspan="1" colspan="1">25 (92.6)</td><td rowspan="1" colspan="1">14 (87.5)</td></tr><tr style="border-right:hidden;border-left:hidden"><td rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;Yes</td><td rowspan="1" colspan="1">2 (7.4)</td><td rowspan="1" colspan="1">2 (12.5)</td></tr><tr style="border-right:hidden;border-left:hidden"><td rowspan="1" colspan="1">&#x000a0;</td><td colspan="2" align="center" rowspan="1"><italic>P</italic>=0.621</td></tr></tbody></table><table-wrap-foot><fn id="TFN12"><p>PGD=primary graft dysfunction; ICU=intensive care unit</p></fn><fn id="TFN13"><label>a</label><p>Statistical differences determined using the &#x003c7;2 test.</p></fn><fn id="TFN14"><label>b</label><p>Statistical differences determined using the Fisher exact test.</p></fn><fn id="TFN15"><label>c</label><p>Patients who died within 48 h after surgery or for whom there was no
information available were not included.</p></fn><fn id="TFN16"><label>*</label><p>Mean values significantly different (<italic>P</italic>&#x0003c;0.05).</p></fn></table-wrap-foot></table-wrap></sec></sec><sec sec-type="discussion"><title>DISCUSSION</title><p>PGD often complicates heart transplantation in the immediate postoperative period,
affecting 10% to 40% of allografts depending on the definition adopted, and
constitutes the main cause of death. Indeed, PGD is responsible for 40% of deaths
within 30 days of transplantation and 18% between 31 days and one
year<sup>[<xref rid="r14" ref-type="bibr">14</xref>]</sup>.
PGD is caused by multiple factors involving problems associated with the heart
donor, the organ recipient and surgical management<sup>[<xref rid="r15" ref-type="bibr">15</xref>]</sup>. The discovery of donor-related biomarkers
that could serve as predictors of allograft quality would facilitate the selection
of potential donors and reduce the frequency of postoperative PGD and mortality of
recipients.</p><p>It has been previously shown that recipients of allografts from older donors
(&#x02265; 50 years) exhibit reduced 1 month, 1 year and 5 year survival
rates<sup>[<xref rid="r16" ref-type="bibr">16</xref>]</sup>.
Additionally, Lund et al.<sup>[<xref rid="r17" ref-type="bibr">17</xref>]</sup> have demonstrated that transplants from older donors
were associated with progressively reduced survival rates of recipients at 1, 5, 10
and 20 years postoperatively, however, this report did not disclose aspects relating
to early morbidity and mortality, particularly during hospital confinement.
Nevertheless, donor age is considered a notable predictor of mortality as well as of
post-transplant complications, such as cardiac allograft
vasculopathy<sup>[<xref rid="r16" ref-type="bibr">16</xref>,<xref rid="r18" ref-type="bibr">18</xref>]</sup>. It is important to
emphasize that the present study focused on donor-related factors influencing
allograft function and clinical evolution of patients within the 30 days period
after transplantation. As shown in this study, the frequency of moderate/severe left
ventricular dysfunction was higher in recipients of organs from older donors, and
such circumstances may determine the future survival of these patients.</p><p>Intravenous administration of relatively high levels of vasoactive catecholamines,
especially noradrenaline, to the donor prior to harvesting or to the recipient
during and after transplant has been considered a predictor of PGD<sup>[<xref rid="r2" ref-type="bibr">2</xref>,<xref rid="r5" ref-type="bibr">5</xref>,<xref rid="r12" ref-type="bibr">12</xref>]</sup>. The
cut-off point for noradrenaline infusion employed in our study was 0.23
&#x000b5;g/kg/min, and rates above this limit were considered to jeopardize the
function of the allograft in the recipient. Earlier reports have described that
noradrenaline diffusion rates between 0.06/0.08 and 0.8 &#x000b5;g/kg/min are
acceptable<sup>[<xref rid="r11" ref-type="bibr">11</xref>,<xref rid="r12" ref-type="bibr">12</xref>,<xref rid="r19" ref-type="bibr">19</xref>]</sup>. However, it is acknowledged that the inotrope
cut-off point represents only one of the clinical parameters of the quality of heart
donors to be considered in evaluating the complex transplant process. Administration
of higher levels of noradrenaline to donors alone does not contraindicate heart
transplantation, since it is not clear that this approach leads to increased
mortality despite its association with PGD. The judicious acceptance of the
effectiveness of noradrenaline doses &#x0003e; 0.23 &#x000b5;g/kg/min might be fundamental
for expanding the number of donor candidates without increasing recipient mortality,
as shown by our study in which 37.2% of the donors received moderate/high levels of
this medication. Noradrenaline has been elected the vasoactive amine of choice in
emergency hospitals and ICUs to treat hypotension refractory to volume in donors, in
spite of its well-known deleterious effects on cardiomyocytes and the potential risk
of PGD in recipients<sup>[<xref rid="r12" ref-type="bibr">12</xref>]</sup>. Our results indicate a significant correlation between
administration to donors of noradrenaline doses &#x0003e; 0.23 &#x000b5;g/kg/min and the
occurrence of left ventricular dysfunction in recipients, as well as protracted CPB
and ICU times. Moreover, our findings suggest a tendency towards increased frequency
of right ventricular dysfunction in transplanted patients who received organ from
donors treated with moderate/high noradrenaline doses.</p><p>Earlier reports have suggested that high levels of the cardiac markers TNF-&#x003b1;,
IL-6, cTnT, procalcitonin and BNP are correlated with the administration of high
doses of inotropic agents and with some degree of PGD<sup>[<xref rid="r2" ref-type="bibr">2</xref>,<xref rid="r5" ref-type="bibr">5</xref>-<xref rid="r8" ref-type="bibr">8</xref>,<xref rid="r12" ref-type="bibr">12</xref>,<xref rid="r20" ref-type="bibr">20</xref>]</sup>.
However, the results presented herein indicate that higher plasma levels of sTNFR1
and sTNFR2 in donors signal a reduction in ICU time for recipients, while enhanced
concentrations of plasma cytokines IL-6 and IL-10 in donors are associated with
reduced hospitalization time for recipients. The inflammatory response of
donors/recipients can be beneficial to some extent, and a balance between pro- and
anti-inflammatory cytokines may be important for the immune system to provide
protection against PGD<sup>[<xref rid="r21" ref-type="bibr">21</xref>]</sup>. Independent of the mechanism of action (feedback loop,
down regulation or cross regulation), the modulator function of the soluble cytokine
receptors and/or of pro- and anti-inflammatory proteins are well
known<sup>[<xref rid="r22" ref-type="bibr">22</xref>,<xref rid="r23" ref-type="bibr">23</xref>]</sup>. Moreover, it is possible
to hypothesize that the cytokine receptors of the allograft in recipients exhibiting
intense inflammatory responses will rapidly reach saturation<sup>[<xref rid="r24" ref-type="bibr">24</xref>]</sup> and, for this reason, such
patients tend to be more resistant to post-transplant inflammation and have a more
successful postoperative evolution (<italic>i.e.</italic> reduced ICU and
hospitalization times).</p><p>It is likely that PGD, with its associated high morbidity and mortality, will remain
a common complication because of the increasing dependence on marginal donors. It is
possible to prevent or minimize PGD by careful matching donors and recipients, and
effective management of donor heart preservation. In this context, the search for
reliable markers of allograft quality must continue and, according to the evidence
gathered so far, a focus on pro- and anti-inflammatory cytokines together with their
receptors would appear to represent a promising approach.</p><sec><title>Study Limitations</title><p>One of the limitations of this study is that the donor population was
pre-selected and all of the organs employed in the transplant procedures were
considered to be of good quality. Another limitation was related to the both
logistical and legal technical difficulties of obtaining blood samples prior to
organ harvesting. In this context, it would have been helpful to analyze blood
samples from rejected donors in order to determine if there were differences in
the concentrations of cardiac markers. Nevertheless, the results presented
herein demonstrated that moderate/high doses of noradrenaline (&#x0003e; 0.23
&#x000b5;g/kg/min) negatively influenced the function of the allograft in the
recipient. Furthermore, our study provided extra information about the possible
protective roles of pro- and anti-inflammatory cytokines and cytokine receptors
(sTNFR1, sTNFR2, IL-6 and IL-10) on the transplanted allograft and the clinical
benefits exerted on the recipients.</p></sec></sec><sec sec-type="conclusions"><title>CONCLUSION</title><p>High levels of sTNFR1, sTNFR2, IL-6 and IL-10 in donors were associated with enhanced
evolution in recipients. Allografts from older donors, or from those treated with
noradrenaline doses &#x0003e;0.23 &#x000b5;g/kg/min, were more frequently affected by PGD
within 30 days of surgery.</p><table-wrap id="t9" orientation="portrait" position="anchor"><table frame="hsides" rules="groups"><colgroup span="1"><col width="10%" span="1"/><col width="90%" span="1"/></colgroup><thead><tr><th align="left" colspan="2" rowspan="1">Authors' roles &#x00026; responsibilities</th></tr></thead><tbody><tr><td valign="top" rowspan="1" colspan="1">RB</td><td rowspan="1" colspan="1">Conception and design study; realization of operations and/or
trials; data collection; analysis and/or data interpretation;
statistical analysis; manuscript redaction or critical review of its
content; final manuscript approval</td></tr><tr><td valign="top" rowspan="1" colspan="1">MDS</td><td rowspan="1" colspan="1">Analysis and/or data interpretation; manuscript redaction or
critical review of its content; final manuscript approval</td></tr><tr><td valign="top" rowspan="1" colspan="1">ALTJ</td><td rowspan="1" colspan="1">Conception and design study; analysis and/or data interpretation;
final manuscript approval</td></tr><tr><td valign="top" rowspan="1" colspan="1">PHNC</td><td rowspan="1" colspan="1">Realization of operations and/or trials; manuscript redaction or
critical review of its content; final manuscript approval</td></tr><tr><td valign="top" rowspan="1" colspan="1">MCVM</td><td rowspan="1" colspan="1">Manuscript redaction or critical review of its content; final
manuscript approval</td></tr><tr><td valign="top" rowspan="1" colspan="1">MAR</td><td rowspan="1" colspan="1">Data collection; final manuscript approval</td></tr><tr><td valign="top" rowspan="1" colspan="1">SAA</td><td rowspan="1" colspan="1">Data collection; manuscript redaction or critical review of its
content; final manuscript approval</td></tr><tr><td valign="top" rowspan="1" colspan="1">CLG</td><td rowspan="1" colspan="1">Realization of operations and/or trials; analysis and/ or data
interpretation; manuscript redaction or critical review of its
content; final manuscript approval</td></tr></tbody></table></table-wrap></sec></body><back><fn-group><fn fn-type="other"><p>This study was carried out at Federal University of Minas Gerais (UFMG), Belo
Horizonte, MG, Brazil.</p></fn><fn fn-type="supported-by"><p>No financial support.</p></fn></fn-group><ref-list><title>REFERENCES</title><ref id="r1"><label>1</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bacal</surname><given-names>F</given-names></name><name><surname>Souza-Neto</surname><given-names>JD</given-names></name><name><surname>Fiorelli</surname><given-names>AI</given-names></name><name><surname>Mejia</surname><given-names>J</given-names></name><name><surname>Marcondes-Braga</surname><given-names>FG</given-names></name><name><surname>Mangini</surname><given-names>S</given-names></name><etal/></person-group><article-title>II Diretriz brasileira de transplante
card&#x000ed;aco</article-title><source>Arq Bras Cardiol</source><year>2010</year><volume>94</volume><issue>1</issue><supplement>suppl. 1</supplement><fpage>e16</fpage><lpage>e73</lpage></element-citation></ref><ref id="r2"><label>2</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lima</surname><given-names>B</given-names></name><name><surname>Rajagopal</surname><given-names>K</given-names></name><name><surname>Petersen</surname><given-names>RP</given-names></name><name><surname>Shah</surname><given-names>AS</given-names></name><name><surname>Soule</surname><given-names>B</given-names></name><name><surname>Felker</surname><given-names>GM</given-names></name><etal/></person-group><article-title>Marginal cardiac allografts do not have increased primary graft
dysfunction in alternate list transplantation</article-title><source>Circulation</source><year>2006</year><volume>114</volume><issue>1</issue><supplement>Suppl</supplement><fpage>I27</fpage><lpage>I32</lpage><pub-id pub-id-type="pmid">16820584</pub-id></element-citation></ref><ref id="r3"><label>3</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Grauhan</surname><given-names>O</given-names></name></person-group><article-title>Screening and assessment of the donor heart</article-title><source>Appl Cardiopulm Pathophysiol</source><year>2011</year><volume>15</volume><fpage>191</fpage><lpage>197</lpage></element-citation></ref><ref id="r4"><label>4</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wood</surname><given-names>KE</given-names></name><name><surname>McCartney</surname><given-names>J</given-names></name></person-group><article-title>Management of the potential organ donor</article-title><source>Transplant Rev</source><year>2007</year><volume>21</volume><issue>4</issue><fpage>204</fpage><lpage>218</lpage></element-citation></ref><ref id="r5"><label>5</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>D'Ancona</surname><given-names>G</given-names></name><name><surname>Santise</surname><given-names>G</given-names></name><name><surname>Falletta</surname><given-names>C</given-names></name><name><surname>Pirone</surname><given-names>F</given-names></name><name><surname>Sciacca</surname><given-names>S</given-names></name><name><surname>Turrisi</surname><given-names>M</given-names></name><etal/></person-group><article-title>Primary graft failure after heart transplantation: the importance
of donor pharmacological management</article-title><source>Transplant Proc</source><year>2010</year><volume>42</volume><issue>3</issue><fpage>710</fpage><lpage>712</lpage><pub-id pub-id-type="pmid">20430153</pub-id></element-citation></ref><ref id="r6"><label>6</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Potapov</surname><given-names>EV</given-names></name><name><surname>Wagner</surname><given-names>FD</given-names></name><name><surname>Loebe</surname><given-names>M</given-names></name><name><surname>Ivanitskaia</surname><given-names>EA</given-names></name><name><surname>M&#x000fc;ller</surname><given-names>C</given-names></name><name><surname>Sodian</surname><given-names>R</given-names></name><etal/></person-group><article-title>Elevated donor cardiac troponin T and procalcitonin indicate two
independent mechanisms of early graft failure after heart
transplantation</article-title><source>Int J Cardiol</source><year>2003</year><volume>92</volume><issue>2-3</issue><fpage>163</fpage><lpage>167</lpage><pub-id pub-id-type="pmid">14659848</pub-id></element-citation></ref><ref id="r7"><label>7</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vorlat</surname><given-names>A</given-names></name><name><surname>Conraads</surname><given-names>VM</given-names></name><name><surname>Jorens</surname><given-names>PG</given-names></name><name><surname>Aerts</surname><given-names>S</given-names></name><name><surname>Van Gorp</surname><given-names>S</given-names></name><name><surname>Vermeulen</surname><given-names>T</given-names></name><etal/></person-group><article-title>Donor B-type natriuretic peptide predicts early cardiac
performance after heart transplantation</article-title><source>J Heart Lung Transplant</source><year>2012</year><volume>31</volume><issue>6</issue><fpage>579</fpage><lpage>584</lpage><pub-id pub-id-type="pmid">22387139</pub-id></element-citation></ref><ref id="r8"><label>8</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Birks</surname><given-names>EJ</given-names></name><name><surname>Burton</surname><given-names>PB</given-names></name><name><surname>Owen</surname><given-names>V</given-names></name><name><surname>Mullen</surname><given-names>AJ</given-names></name><name><surname>Hunt</surname><given-names>D</given-names></name><name><surname>Banner</surname><given-names>NR</given-names></name><etal/></person-group><article-title>Elevated tumor necrosis factor-alpha and interleukin-6 in
myocardium and serum of malfunctioning donor hearts</article-title><source>Circulation</source><year>2000</year><volume>102</volume><issue>19</issue><supplement>Suppl 3</supplement><fpage>III352</fpage><lpage>III358</lpage><pub-id pub-id-type="pmid">11082413</pub-id></element-citation></ref><ref id="r9"><label>9</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Segovia</surname><given-names>J</given-names></name><name><surname>Cos&#x000ed;o</surname><given-names>MD</given-names></name><name><surname>Barcel&#x000f3;</surname><given-names>JM</given-names></name><name><surname>Bueno</surname><given-names>MG</given-names></name><name><surname>Pav&#x000ed;a</surname><given-names>PG</given-names></name><name><surname>Burgos</surname><given-names>R</given-names></name><etal/></person-group><article-title>RADIAL: a novel primary graft failure risk score in heart
transplantation</article-title><source>J Heart Lung Transplant</source><year>2011</year><volume>30</volume><issue>6</issue><fpage>644</fpage><lpage>651</lpage><pub-id pub-id-type="pmid">21470878</pub-id></element-citation></ref><ref id="r10"><label>10</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Manukyan</surname><given-names>MC</given-names></name><name><surname>Alvernaz</surname><given-names>CH</given-names></name><name><surname>Poynter</surname><given-names>JA</given-names></name><name><surname>Wang</surname><given-names>Y</given-names></name><name><surname>Brewster</surname><given-names>BD</given-names></name><name><surname>Weil</surname><given-names>BR</given-names></name><etal/></person-group><article-title>Interleukin-10 protects the ischemic heart from reperfusion
injury via the STAT3 pathway</article-title><source>Surgery</source><year>2011</year><volume>150</volume><issue>2</issue><fpage>231</fpage><lpage>239</lpage><pub-id pub-id-type="pmid">21719057</pub-id></element-citation></ref><ref id="r11"><label>11</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shemie</surname><given-names>SD</given-names></name><name><surname>Ross</surname><given-names>H</given-names></name><name><surname>Pagliarello</surname><given-names>J</given-names></name><name><surname>Baker</surname><given-names>AJ</given-names></name><name><surname>Greig</surname><given-names>PD</given-names></name><name><surname>Brand</surname><given-names>T</given-names></name><etal/><collab>Pediatric Recommendations Group</collab></person-group><article-title>Organ donor management in Canada: recommendations of the forum on
Medical Management to Optimize Donor Organ Potential</article-title><source>CMAJ</source><year>2006</year><volume>174</volume><issue>6</issue><fpage>S13</fpage><lpage>S32</lpage><pub-id pub-id-type="pmid">16534070</pub-id></element-citation></ref><ref id="r12"><label>12</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Santise</surname><given-names>G</given-names></name><name><surname>D'Ancona</surname><given-names>G</given-names></name><name><surname>Falletta</surname><given-names>C</given-names></name><name><surname>Pirone</surname><given-names>F</given-names></name><name><surname>Sciacca</surname><given-names>S</given-names></name><name><surname>Turrisi</surname><given-names>M</given-names></name><etal/></person-group><article-title>Donor pharmacological hemodynamic support is associated with
primary graft failure in human heart transplantation</article-title><source>Interact Cardiovasc Thorac Surg</source><year>2009</year><volume>9</volume><issue>3</issue><fpage>476</fpage><lpage>479</lpage><pub-id pub-id-type="pmid">19564203</pub-id></element-citation></ref><ref id="r13"><label>13</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Braulio</surname><given-names>R</given-names></name><name><surname>Gelape</surname><given-names>CL</given-names></name><name><surname>Brasileiro Filho</surname><given-names>G</given-names></name><name><surname>Moreira</surname><given-names>MC</given-names></name></person-group><article-title>Terminal ischemic cardiomyopathy associated with complication of
stenting in the treatment of acute myocardial infarction</article-title><source>Rev Bras Cir Cardiovasc</source><year>2011</year><volume>26</volume><issue>3</issue><fpage>481</fpage><lpage>484</lpage><pub-id pub-id-type="pmid">22086588</pub-id></element-citation></ref><ref id="r14"><label>14</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dronavalli</surname><given-names>VB</given-names></name><name><surname>Rogers</surname><given-names>CA</given-names></name><name><surname>Banner</surname><given-names>NR</given-names></name></person-group><article-title>Primary cardiac allograft dysfunction-validation of a clinical
definition</article-title><source>Transplantation</source><year>2015</year><volume>99</volume><issue>9</issue><fpage>1919</fpage><lpage>1925</lpage><pub-id pub-id-type="pmid">25742423</pub-id></element-citation></ref><ref id="r15"><label>15</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kobashigawa</surname><given-names>J</given-names></name><name><surname>Zuckermann</surname><given-names>A</given-names></name><name><surname>MacDonald</surname><given-names>P</given-names></name><name><surname>Leprince</surname><given-names>P</given-names></name><name><surname>Esmailian</surname><given-names>F</given-names></name><name><surname>Luu</surname><given-names>M</given-names></name><etal/></person-group><article-title>Report from a consensus conference on primary graft dysfunction
after cardiac transplantation</article-title><source>J Heart Lung Transplant</source><year>2014</year><volume>33</volume><issue>4</issue><fpage>327</fpage><lpage>340</lpage><pub-id pub-id-type="pmid">24661451</pub-id></element-citation></ref><ref id="r16"><label>16</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gupta</surname><given-names>D</given-names></name><name><surname>3rd</surname><given-names>Piacentino V</given-names></name><name><surname>Macha</surname><given-names>M</given-names></name><name><surname>Singhal</surname><given-names>AK</given-names></name><name><surname>Gaughan</surname><given-names>JP</given-names></name><name><surname>McClurken</surname><given-names>JB</given-names></name><etal/></person-group><article-title>Effect of older donor age on risk for mortality after heart
transplantation</article-title><source>Ann Thorac Surg</source><year>2004</year><volume>78</volume><issue>3</issue><fpage>890</fpage><lpage>899</lpage><pub-id pub-id-type="pmid">15337016</pub-id></element-citation></ref><ref id="r17"><label>17</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lund</surname><given-names>LH</given-names></name><name><surname>Edwards</surname><given-names>LB</given-names></name><name><surname>Kucheryavaya</surname><given-names>AY</given-names></name><name><surname>Dipchand</surname><given-names>AI</given-names></name><name><surname>Benden</surname><given-names>C</given-names></name><name><surname>Christie</surname><given-names>JD</given-names></name><etal/></person-group><article-title>The Registry of the International Society for Heart and Lung
Transplantation: Thirtieth Official Adult Heart Transplant Report-2013;
focus theme: age</article-title><source>J Heart Lung Transplant</source><year>2013</year><volume>32</volume><issue>10</issue><fpage>951</fpage><lpage>964</lpage><pub-id pub-id-type="pmid">24054804</pub-id></element-citation></ref><ref id="r18"><label>18</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lietz</surname><given-names>K</given-names></name><name><surname>John</surname><given-names>R</given-names></name><name><surname>Mancini</surname><given-names>DM</given-names></name><name><surname>Edwards</surname><given-names>NM</given-names></name></person-group><article-title>Outcomes in cardiac transplant recipients using allografts from
older donors versus mortality on the transplant waiting list: Implications
for donor selection criteria</article-title><source>J Am Coll Cardiol</source><year>2004</year><volume>43</volume><issue>9</issue><fpage>1553</fpage><lpage>1561</lpage><pub-id pub-id-type="pmid">15120811</pub-id></element-citation></ref><ref id="r19"><label>19</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Smits</surname><given-names>JM</given-names></name><name><surname>De Pauw</surname><given-names>M</given-names></name><name><surname>de Vries</surname><given-names>E</given-names></name><name><surname>Rahmel</surname><given-names>A</given-names></name><name><surname>Meiser</surname><given-names>B</given-names></name><name><surname>Laufer</surname><given-names>G</given-names></name><etal/></person-group><article-title>Donor scoring system for heart transplantation and the impact on
patient survival</article-title><source>J Heart Lung Transplant</source><year>2012</year><volume>31</volume><issue>4</issue><fpage>387</fpage><lpage>397</lpage><pub-id pub-id-type="pmid">22177692</pub-id></element-citation></ref><ref id="r20"><label>20</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Venkateswaran</surname><given-names>RV</given-names></name><name><surname>Ganesh</surname><given-names>JS</given-names></name><name><surname>Thekkudan</surname><given-names>J</given-names></name><name><surname>Steeds</surname><given-names>R</given-names></name><name><surname>Wilson</surname><given-names>IC</given-names></name><name><surname>Mascaro</surname><given-names>J</given-names></name><etal/></person-group><article-title>Donor cardiac troponin-I: a biochemical surrogate of heart
function</article-title><source>Eur J Cardiothorac Surg</source><year>2009</year><volume>36</volume><issue>2</issue><fpage>286</fpage><lpage>292</lpage><pub-id pub-id-type="pmid">19394856</pub-id></element-citation></ref><ref id="r21"><label>21</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Venkateswaran</surname><given-names>RV</given-names></name><name><surname>Dronavalli</surname><given-names>V</given-names></name><name><surname>Lambert</surname><given-names>PA</given-names></name><name><surname>Steeds</surname><given-names>RP</given-names></name><name><surname>Wilson</surname><given-names>IC</given-names></name><name><surname>Thompson</surname><given-names>RD</given-names></name><etal/></person-group><article-title>The proinflammatory environment in potential heart and lung
donors: prevalence and impact of donor management and hormonal
therapy</article-title><source>Transplantation</source><year>2009</year><volume>88</volume><issue>4</issue><fpage>582</fpage><lpage>588</lpage><pub-id pub-id-type="pmid">19696643</pub-id></element-citation></ref><ref id="r22"><label>22</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sivalingam</surname><given-names>SP</given-names></name><name><surname>Thumboo</surname><given-names>J</given-names></name><name><surname>Vasoo</surname><given-names>S</given-names></name><name><surname>Thio</surname><given-names>ST</given-names></name><name><surname>Tse</surname><given-names>C</given-names></name><name><surname>Fong</surname><given-names>KY</given-names></name></person-group><article-title>In vivo pro- and anti-inflammatory cytokines in normal and
patients with rheumatoid arthritis</article-title><source>Ann Acad Med Singapore</source><year>2007</year><volume>36</volume><issue>2</issue><fpage>96</fpage><lpage>99</lpage><pub-id pub-id-type="pmid">17364074</pub-id></element-citation></ref><ref id="r23"><label>23</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Radstake</surname><given-names>TR</given-names></name><name><surname>van Lent</surname><given-names>PL</given-names></name><name><surname>Pesman</surname><given-names>GJ</given-names></name><name><surname>Blom</surname><given-names>AB</given-names></name><name><surname>Sweep</surname><given-names>FG</given-names></name><name><surname>R&#x000f6;nnelid</surname><given-names>J</given-names></name><etal/></person-group><article-title>High production of proinflammatory and Th1 cytokines by dendritic
cells from patients with rheumatoid arthritis, and down regulation upon
FcgammaR triggering</article-title><source>Ann Rheum Dis</source><year>2004</year><volume>63</volume><issue>6</issue><fpage>696</fpage><lpage>702</lpage><pub-id pub-id-type="pmid">15140777</pub-id></element-citation></ref><ref id="r24"><label>24</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pussieldi</surname><given-names>GA</given-names></name><name><surname>Gomes</surname><given-names>EC</given-names></name><name><surname>Veneroso</surname><given-names>CE</given-names></name><name><surname>De Paz</surname><given-names>JA</given-names></name><name><surname>Fonseca</surname><given-names>TR</given-names></name><name><surname>Mendes</surname><given-names>TT</given-names></name><etal/></person-group><article-title>Soluble tumour necrosis factor receptor-1 (sTNFR1) levels are
positively associated with exercise intensity in athletes after strenuous
off-road cycling</article-title><source>J Sports Med Phys Fitness</source><year>2014</year><volume>54</volume><issue>2</issue><fpage>225</fpage><lpage>231</lpage><pub-id pub-id-type="pmid">24509995</pub-id></element-citation></ref></ref-list></back></article>